XKEM ----- Most Recent Press Releases and Financial Statements
XECHEM ANNOUNCES SUCCESSFUL CAPITAL RAISE BY CEPTOR CORPORATION (XECHEM RECEIVES APPROXIMATELY $1.28 MILLION AS PART OF THE TRANSACTION)
XECHEM ANNOUNCES SIGNIFICANT PROGRESS IN THE DEVELOPMENT OF ITS SICKLE CELL DISEASE DRUG (NICOSAN™ / HEMOXIN™)
XECHEM RECEIVES A BROAD U.S. PATENT FOR SECOND GENERATION PACLITAXEL
PROVISIONAL PATENT APPLICATION FILED FOR EPILEPSY COMPOUND C-202 BY XECHEM’S SUBSIDIARY, CEPTOR CORPORATION
XECHEM Awarded ADDITIONAL European Patent for anti-cancer drug paclitaxel
XECHEM ANNOUNCES FAVORABLE RULING BY US COURT OF APPEALS IN ITS antitrust case against Bristol Myers Squibb
XECHEM announces Current Public Filing
XECHEM MAJORITY-OWNED SUBSIDIARY, CEPTOR CORPORATION,
RECEIVES NIH GRANT FOR HEARING LOSS STUDY
Xechem Announces independent financing to ceptor subsidiary
XECHEM announces execution of definitive AGREEMENT documents regarding business COOPERATION and cash infusion pact WITH alembic, limited, A major indian pHARMACEUTICAL COMPANY
XECHEM PRESENTS UPDATE ON NIPRISAN – Nix-0699
Xechem and Ceptor Announce Capitalization and financing Plan
Xechem International COMPLETES Ceptor TRANSACTION
Xechem International to Acquire Ceptor Corporation
WILLIAM PURSLEY NAMED PRESIDENT AND CHIEF OPERATING OFFICER OF XECHEM INTERNATIONAL, INC.
XECHEM RECEIVES PACLITAXEL PATENT
XECHEM RETAINS PHARM-OLAM AND HYMAN, PHELPS AND McNAMARA FOR HEMOXIN™ IND
Biotech Turnaround Guru, William Pursley, Named Vice-Chairman Of Xechem International
Xechem Receives Phase I NIH Grant for Treatment of Sickle Cell Disease with Niprisan -Hemoxin-
Xechem's Sickle Cell Drug, NIPRISAN -HEMOXIN- Granted Orphan Drug Status by the FDA
XECHEM ANNOUNCES LAUNCH OF NICOSAN™ (formerly “Niprisan”)
XECHEM FORMS XECHEM PHARMACEUTICALS NIGERIA LTD.
138,000,000 NEW RECORD VOLUME ---- XKEM HISTORY !!!!!!Thanks Bristol Myers for your 4,200,000 !!!!!
